

S.4 Systemic, biologic therapies (short term)

Intervention	Population – psoriasis phenotype	Prior biologics received	N achieving remission (clear/nearly clear or PASI75)			N experiencing: Withdrawal due to drug toxicity or serious adverse events		
			Intervention	Placebo	Active comparator [†]	Intervention	Placebo	Active comparator [†]
Infliximab	Adults with severe plaque psoriasis and prior biologic exposure	Unclear	723/1000	0/1000	-	NA	NA	NA
Etanercept	Adults with severe plaque psoriasis and prior biologic exposure	Included etanercept, infliximab, and adalimumab (proportions unclear)	370/1000	NA	Ustekinumab 556/1000	NA	NA	NA
Ustekinumab	Adults with severe plaque psoriasis and prior biologic exposure	Included etanercept, infliximab, and adalimumab (proportions unclear)	619/1000	170/1000	-	NA	NA	NA
Adalimumab	Adults with severe plaque psoriasis	Etanercept (32.1%), alefacept (23.1%), ustekinumab (23.1%), efalizumab (21.8%), infliximab (20.5%), and other (17.9%)	654/1000	NA	No prior biologic 744/1000	NA	NA	NA

[†] An active comparator will only be included if no placebo comparison is available; the standard intervention will be chosen if multiple active comparators are available

NA: Not available

-: Active comparison not reported as placebo comparison was available